Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

25.83USD
23 Jul 2018
Change (% chg)

$-0.07 (-0.27%)
Prev Close
$25.90
Open
$25.80
Day's High
$25.89
Day's Low
$25.80
Volume
1,455
Avg. Vol
75,355
52-wk High
$36.38
52-wk Low
$21.27

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $1,919.56
Shares Outstanding(Mil.): 53.83
Dividend: --
Yield (%): --

Financials

  TBPH.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -4.62 -- --
ROI: -57.04 15.07 14.61
ROE: -82.78 16.60 16.34

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

27 Feb 2018

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

29 Jan 2018

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

29 Jan 2018

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $62.68 +0.16
The Medicines Company (MDCO.OQ) $39.91 +0.11
GlaxoSmithKline plc (GSK.L) 1,568.00 +18.20
AstraZeneca plc (AZN.L) 5,589.00 0.00
Novartis AG (NOVN.S) CHF81.98 -0.22

Earnings vs. Estimates